Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 2/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | STAT5B | P51692 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11528826 | 0.89 | MIF (0.38) | MLYCDHDAC1HDAC8HDAC6STAT5B | |
| SCHEMBL7239028 | 0.88 | MLYCD (0.41) | LTB4R2MLYCDRIPK1HDAC1HDAC8 | |
| SCHEMBL3772650 | 0.84 | MT-CO2 (0.36) | PTGIRPTGDRLTB4R2RIPK1HDAC1 | |
| SCHEMBL3349318 | 0.84 | MLYCD (0.41) | LTB4R2MLYCD | |
| SCHEMBL3160941 | 0.82 | MT-CO2 (0.38) | PTGIRPTGDRLTB4R2RIPK1HDAC1 | |
| SCHEMBL4832488 | 0.82 | HDAC1 (0.48) | PTGIRPTGDRLTB4R2HDAC1HDAC8 | |
| SCHEMBL7235054 | 0.81 | RXRA (0.35) | LTB4R2HDAC1HDAC8HDAC6STAT5B | |
| SCHEMBL266144 | 0.81 | MT-CO2 (0.46) | MLYCDMT-CO2 | |
| SCHEMBL6302058 | 0.81 | HDAC1 (0.36) | PTGIRMLYCDHDAC1HDAC8HDAC6 | |
| SCHEMBL3160825 | 0.81 | TSHR (0.37) | PTGIRPTGDRLTB4R2RIPK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
| US-6555541-B1 | P2X7 receptor antagonists for treatment of inflammatory respiratory system disorders such as asthma; for example, 2-(3,4-Difluorophenylamino)-N-(2-methyl-5-piperazin-1-yl-methyl-phenyl) -acetamide, trihydrochloride | ASTRAZENECA UK LIMITED (GB) | 2003-04-29 | — | — | US | disclosed |
| EP-1185522-A1 | SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000071529-A1 | SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS | ASTRAZENECA AB (SE) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | PTGIR 1004/4885PTGDR 1042/4885LTB4R2 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.